Avista, Nordic Ink $439M Deal To Acquire Swiss Drugmaker
Under the terms of the deal, Avista's and Nordic's subsidiary Pharma Strategy Partners GmbH will purchase all outstanding Acino shares for 115 Swiss francs (US$127.66) per share, a 33 percent markup on Tuesday's closing share price. Following completion of the tender offer, Acino will be delisted from the SIX Swiss Exchange, the company said.
Acino's board of directors praised...
To view the full article, register now.